阻塞性睡眠呼吸暂停及其持续气道正压治疗对急性冠脉综合征患者心血管事件患病率的影响(ISAACC研究):一项随机对照试验
ISAACC研究为多中心随机对照试验,纳入西班牙15家医院无嗜睡的急性冠脉综合征患者,呼吸多导睡眠图检出OSA者随机接受CPAP联合常规治疗或单纯常规治疗。
要点
- 无嗜睡ACS患者中,OSA存在与心血管事件患病率增加无关。
- CPAP治疗未显著降低ACS合并OSA患者的心血管事件患病率。
核心结论
- 在无嗜睡的急性冠脉综合征患者中,阻塞性睡眠呼吸暂停的存在与心血管事件患病率增加无关。
- 持续气道正压治疗未显著降低心血管事件患病率。
研究设计与样本
- 多中心、开放标签、平行组随机对照试验,在西班牙15家医院开展。
- 纳入因急性冠脉综合征入院、年龄18岁及以上、无嗜睡的患者,入院24-72小时内行呼吸多导睡眠图。
- OSA患者按1:1随机分配至CPAP联合常规治疗组或单纯常规治疗组,另设无OSA的参照组。
主要发现
- 心血管事件患病率似乎与CPAP依从性或OSA严重程度无关。
- CPAP组629例中464例(74%)发生1538例严重不良事件,常规治疗组626例中406例(65%)发生1764例严重不良事件。
临床怎么用
- 对于无嗜睡的急性冠脉综合征合并OSA患者,不应仅基于改善心血管预后目的而常规启动CPAP治疗。
- OSA的存在不应被视为该人群心血管事件风险增加的独立因素。
局限性
- 研究为开放标签设计,干预措施无法对研究者和患者设盲。
- 研究纳入的是无嗜睡患者,结果不能推广至有嗜睡症状的OSA患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the improvement in the prognosis of acute coronary syndrome (ACS), substantial morbidity and mortality remain. We aimed to evaluate the effect of obstructive sleep apnoea (OSA) and its treatment with continuous positive airway pressure (CPAP) on the clinical evolution of patients with ACS. METHODS: We designed a multicentre, open-label, parallel-group, randomised controlled trial of patients with ACS at 15 hospitals in Spain. Eligible non-sleepy patients were men and women aged 18 years and older, admitted to hospital for documented symptoms of ACS. All patients underwent respiratory polygraphy during the first 24-72 h after admission. OSA patients were randomly assigned (1:1) to CPAP treatment plus usual care (CPAP group) or usual care alone (UC group) by a computerised system available 24 h a day. A group of patients with ACS but without OSA was also included as a reference group. Because of the nature of the intervention, the trial intervention could not be masked to either investigators or patients. Patients were monitored and followed for a minimum of 1 year. Patients were examined at the time of inclusion; after 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months; and every 12 months thereafter, if applicable, during the follow-up period. The primary endpoint was the prevalence of a composite of cardiovascular events (cardiovascular death or non-fatal events [Acute myocardial infarction, non-fatal stroke, hospital admission for heart failure, and new hospitalisations for unstable angina or transient ischaemic attack]) in patients followed up for a minimum of 1 year. The primary analysis was done according to the intention-to-treat principle. This study is registered with Clinicaltrials.gov, NCT01335087 and is now closed. FINDINGS: Between April 25, 2011, and Feb 2, 2018, a total of 2834 patients with ACS had respiratory polygraphy, of whom 2551 (90·01%) were recruited. 1264 (49·55%) patients had OSA and were randomly assigned to the CPAP group (n=633) or the UC group (n=631). 1287 (50·45%) patients did not have OSA, of whom 603 (46·85%) were randomly assigned to the reference group. Patients were followed up for a median of 3·35 years (IQR 1·50-5·31). The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up. Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73). The prevalence of cardiovascular events was similar between patients in the reference group (90 [15%] events) and those in the UC group (102 (17%) events) during follow-up (1·01 [0·76-1·35]; p=0·93). The prevalence of cardiovascular events seem not to be related to CPAP compliance or OSA severity. 464 (74%) of 629 patients in the CPAP group had 1538 serious adverse events and 406 (65%) of 626 patients in the UC group had 1764 serious adverse events. INTERPRETATION: Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence. FUNDING: ResMed (Australia), Fondo de Investigación Sanitaria (Fondo Europeo de Desarrollo Regional), the Spanish Respiratory Society, the Catalonian Cardiology Society, Esteve-Teijin, Oxigen Salud, and ALLER.
引用
- Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Respir Med. 2019. PMID: 31839558. doi:10.1016/S2213-2600(19)30271-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。